Baxter International Inc at Barclays Global Healthcare Conference Transcript
All right. Thanks, everyone, for joining us here for an afternoon session around the MedTech Track. I'm Kristen Stewart, the device analyst. I am very happy to have Baxter International here with us. So we have Jay Saccaro, the company's CFO; as well as Clare Trachtman, Investor Relations. We're going to keep this very interactive, keep you guys awake and alert. And we're going to be using the audience-response questions quite a bit. So the lovely BlackBerry-like devices at your seats. Please grab it, and get ready for the first question that I'm going to fire off. So just a little bit of background context here. So Baxter's long-range plan calls for a sales CAGR of 5% over the 2018 to 2023 period. They're actually expecting 4% to 5% growth in 2018 to 2020, but I want to ask about your view on the achievability of the acceleration to 5% to 6% over the 2020 to 2023 period, again, kind of, 4% to 5%, 5% to 6%, getting to the total of 5% over the 5 year. So how do you view this growth goal, too aggressive, reasonable or conservative
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |